Novartis Eyes Broader Market As Pluvicto Hits Mark In Pivotal Second-Line mCRPC Trial
Peak Sales Estimates Could Increase
The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.
You may also be interested in...
A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.